These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34384556)

  • 1. Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial.
    Hsia J; Szarek M; Anand S; Patel MR; Debus S; Berkowitz SD; Muehlhofer E; Haskell LP; Bauersachs RM; Bonaca MP
    J Am Coll Cardiol; 2021 Aug; 78(7):757-759. PubMed ID: 34384556
    [No Abstract]   [Full Text] [Related]  

  • 2. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial.
    Bauersachs RM; Szarek M; Brodmann M; Gudz I; Debus ES; Nehler MR; Anand SS; Patel MR; Hess CN; Capell WH; Rogers K; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP;
    J Am Coll Cardiol; 2021 Jul; 78(4):317-326. PubMed ID: 34010631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VOYAGER PAD contributes to medical therapy for peripheral artery disease.
    Farber A
    J Vasc Surg; 2020 Dec; 72(6):1843-1844. PubMed ID: 33222822
    [No Abstract]   [Full Text] [Related]  

  • 4. The Voyager PAD Trial - New Path for Post-revascularisation PAD Patients.
    Debus ES; Nehler MR;
    Eur J Vasc Endovasc Surg; 2020 May; 59(5):699-700. PubMed ID: 32307302
    [No Abstract]   [Full Text] [Related]  

  • 5. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
    Lapébie FX; Aboyans V; Lacroix P; Constans J; Boulon C; Messas E; Ferrières J; Bongard V; Bura-Rivière A
    Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):439-449. PubMed ID: 34330647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
    Capell WH; Bonaca MP; Nehler MR; Chen E; Kittelson JM; Anand SS; Berkowitz SD; Debus ES; Fanelli F; Haskell L; Patel MR; Bauersachs R; Hiatt WR
    Am Heart J; 2018 May; 199():83-91. PubMed ID: 29754671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatments for peripheral artery disease.
    Bartholomew J; Bishop GJ
    Cleve Clin J Med; 2020 May; 87(5 suppl 1):21-25. PubMed ID: 32349971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
    Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
    Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of rivaroxaban compared with warfarin in patients undergoing peripheral arterial procedures.
    Talukdar A; Wang SK; Czosnowski L; Mokraoui N; Gupta A; Fajardo A; Dalsing M; Motaganahalli R
    J Vasc Surg; 2017 Oct; 66(4):1143-1148. PubMed ID: 28712814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
    Wheeler M; Chan N; Eikelboom J
    Future Cardiol; 2020 Nov; 16(6):597-611. PubMed ID: 32633570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
    Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T
    Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation.
    Rivera-Caravaca JM; Camelo-Castillo A; Ramírez-Macías I; Gil-Pérez P; López-García C; Esteve-Pastor MA; Orenes-Piñero E; Tello-Montoliu A; Marín F
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?
    Bauersachs R; Zannad F
    Thromb Haemost; 2018 May; 118(S 01):S12-S22. PubMed ID: 29566413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Ultee KHJ; Steunenberg SL; Schouten O
    N Engl J Med; 2020 Nov; 383(21):2089-2090. PubMed ID: 33207107
    [No Abstract]   [Full Text] [Related]  

  • 16. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Gremmel T
    N Engl J Med; 2020 Nov; 383(21):2090. PubMed ID: 33207108
    [No Abstract]   [Full Text] [Related]  

  • 17. Rivaroxaban in Peripheral Artery Disease after Revascularization. Reply.
    Bonaca MP; Bauersachs RM; Hiatt WR
    N Engl J Med; 2020 Nov; 383(21):2090-2091. PubMed ID: 33207109
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacological management of obstructive peripheral arterial disease: two case reports.
    Détriché G; Lanéelle D; Radureau C
    Hosp Pract (1995); 2021 Dec; 49(5):379-383. PubMed ID: 34278930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
    Cowie MR; Lamy A; Levy P; Mealing S; Millier A; Mernagh P; Cristeau O; Bowrin K; Briere JB
    Cardiovasc Res; 2020 Sep; 116(11):1918-1924. PubMed ID: 31807773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.